NCT06846541Phase 3Active not recruiting

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

Study sponsor: Alumis Inc · ALMS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-11Estimated
Enrollment · participants1680Estimated
Source updated2026-04-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source